---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-046258"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:21:54.336588+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics amends ATM agreement to increase offering capacity to up to $75M

## Summary
- Prior ATM: sold 14.7M shares for ~$15M through Dec 2, 2024 to Oct 24, 2025.
- Amendment raises aggregate offering to $75M (excl. prior sales) under new S-3 effective Nov 14, 2024.
- New prospectus supplement dated Oct 24, 2025; agent Leerink commission up to 3% of gross proceeds.
- Proceeds intended for R&D, working capital, and general corporate purposes.
- Prior ATM prospectus terminated; no further sales under that facility.

## SEC filing metadata
- accession: 0001628280-25-046258
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828025046258/0001628280-25-046258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828025046258/cntx-20251024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-046258
- JSON: https://secwatch.observer/filing/0001628280-25-046258.json
- Plain text: https://secwatch.observer/filing/0001628280-25-046258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.